Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation

Table 3 Risk of adverse clinical outcomes in OAC treated patients with or without APT treatment

Outcomes	OAC with APT (No.of patients) (n = 159)	OAC without APT (No.of patients) (n = 142)	Adjusted^a HR (95% CI)	P value
MACEs	33 (20.75)	29 (20.42)	1.18 (0.66–2.12)	0.583
All-cause death	9(5.66)	20(14.08)	0.36(0.16–0.85)	0.020
Non-fatal MI	0(0)	0(0)	-	-
Non-fatal stroke	19(11.95)	7(4.93)	3.46(1.35–8.88)	0.010
Systemic embolism	5(3.14)	2(1.41)	2.64(0.46–15.33)	0.278
Bleedings	52(32.70)	34 (23.94)	1.77(1.04–3.03)	0.036
BARC ≥ 3	9(5.66)	5(3.52)	2.03(0.63–6.52)	0.235
BARC ≥ 2	18(11.32)	7(4.93)	2.71(1.07–6.90)	0.036
Net clinical outcomes^b	38(23.90)	32(22.54)	1.30(0.73–2.29)	0.372

MACEs Major adverse cardiovascular events, including all-cause death, non-fatal MI, non-fatal stroke and systemic embolism, OAC Oral anticoagulant, BARC Bleeding Academic Research Consortium, HR Hazard ratio, CI Confidence interval
^aFor MACEs, HR was adjusted by the variables including sex, age, BMI, previous myocardial infarction, previous stroke, statins, persistent atrial fibrillation. For bleedings, HR was adjusted by the variables including sex, age, BMI, statins, persistent atrial fibrillation, previous bleeding; For net clinical outcomes, HR was adjusted by the variables including sex, age, BMI, statins, persistent atrial fibrillation, previous bleeding, previous myocardial infarction, and previous stroke;
^bIncluding MACEs and BARC ≥ 3 type bleeding events

ISSN: 1477-9560